首页 > 最新文献

ChemMedChem最新文献

英文 中文
Serum Circulating mRNA Panel for the Early Detection of Gastric Cancer: A Potential Biomarker Test. 用于胃癌早期检测的血清循环 mRNA 分析:一种潜在的生物标记物检测
IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-09-05 DOI: 10.1002/cmdc.202400523
Da Han, Xinyu Peng, Xiaoyan Teng, Qian Ma

Circulating free messenger RNAs (cfmRNAs) in serum have emerged as potential noninvasive biomarkers for cancer diagnosis, including gastric cancer (GC). This study utilized RNA-sequencing data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to identify a training set of 100 differentially expressed genes (DEGs) specific to GC patients. Employing a support vector machine (SVM) classification, we narrowed down the candidate gene set to 23, which was further refined to 4 genes-DMBX1, EVX1, MAL, and PIWIL1-after validation through reverse transcription quantitative polymerase chain reaction (RT-qPCR). The diagnostic performance of mRNA panels, particularly the combinations of DMBX1 with EVX1 and EVX1 with PIWIL1, was exceptional, achieving area under the curve (AUC) values of 0.800, sensitivities of 90.0%, and specificities of 80.0%. The accuracy of these biomarkers was corroborated through various machine learning algorithms, underscoring their robust diagnostic potential. The findings of this study are poised to significantly influence clinical practice by providing robust tools for early GC detection. As these biomarkers undergo further investigation and validation, they hold promise to become integral to the diagnostic for GC.

血清中的循环游离信使RNA(cfmRNA)已成为诊断癌症(包括胃癌)的潜在非侵入性生物标记物。本研究利用癌症基因组图谱(TCGA)和基因表达总库(GEO)数据库中的RNA测序数据,确定了100个胃癌患者特有的差异表达基因(DEG)训练集。通过支持向量机(SVM)分类,我们将候选基因集缩小到23个,经过反转录定量聚合酶链反应(RT-qPCR)验证后,候选基因集进一步细化为4个基因--DMBX1、EVX1、MAL和PIWIL1。mRNA 面板的诊断性能非常出色,尤其是 DMBX1 与 EVX1 和 EVX1 与 PIWIL1 的组合,其曲线下面积 (AUC) 值达到 0.800,灵敏度为 90.0%,特异性为 80.0%。这些生物标志物的准确性通过各种机器学习算法得到了证实,彰显了其强大的诊断潜力。这项研究的结果将为早期 GC 检测提供强有力的工具,从而对临床实践产生重大影响。随着这些生物标志物得到进一步的研究和验证,它们有望成为 GC 诊断的组成部分。
{"title":"Serum Circulating mRNA Panel for the Early Detection of Gastric Cancer: A Potential Biomarker Test.","authors":"Da Han, Xinyu Peng, Xiaoyan Teng, Qian Ma","doi":"10.1002/cmdc.202400523","DOIUrl":"https://doi.org/10.1002/cmdc.202400523","url":null,"abstract":"<p><p>Circulating free messenger RNAs (cfmRNAs) in serum have emerged as potential noninvasive biomarkers for cancer diagnosis, including gastric cancer (GC). This study utilized RNA-sequencing data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to identify a training set of 100 differentially expressed genes (DEGs) specific to GC patients. Employing a support vector machine (SVM) classification, we narrowed down the candidate gene set to 23, which was further refined to 4 genes-DMBX1, EVX1, MAL, and PIWIL1-after validation through reverse transcription quantitative polymerase chain reaction (RT-qPCR). The diagnostic performance of mRNA panels, particularly the combinations of DMBX1 with EVX1 and EVX1 with PIWIL1, was exceptional, achieving area under the curve (AUC) values of 0.800, sensitivities of 90.0%, and specificities of 80.0%. The accuracy of these biomarkers was corroborated through various machine learning algorithms, underscoring their robust diagnostic potential. The findings of this study are poised to significantly influence clinical practice by providing robust tools for early GC detection. As these biomarkers undergo further investigation and validation, they hold promise to become integral to the diagnostic for GC.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142131374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two-step synthesis of enantiomerically pure morphans from (R)-carvone. 从 (R)-carvone 分两步合成对映体纯吗啡。
IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-09-05 DOI: 10.1002/cmdc.202400596
Bernhard Wünsch, Giuliana Costanzo, Giuseppe Cosentino, Lorella Pasquinucci, Emanuele Amata, Dirk Schepmann

Enantiomerically pure 4-hydroxymorphan-7-ones were prepared in two steps from the natural product (R)-carvone. At first, the isopropenyl moiety of (R)-carvone was converted into the epoxide 7. A Domino reaction consisting of epoxide opening with primary amines followed by intramolecular conjugate addition of the resulting secondary amines at the α,β-unsaturated ketone established the morphan scaffold. This novel morphan synthesis allowed the modification of the bicyclic system at three positions resulting in 26 diverse morphans. Various primary amines led to morphans 8‒13 with different N-substituents. Acylation or water elimination followed by hydrogenation led to esters 15 and 16 or the morphan 18 without a hydroxy moiety. The benzylidenemorphans 25a and 26a were prepared by condensation of the ketones 11a and 12a with benzaldehyde. Finally, the α-methylene ketone of 11a and 12a was exploited to obtain indolomorphans, quinolinomorphans, pyrimidinomorphans and pyrazolomorphans. Affinity of the novel morphans at opioid receptors MOR, DOR and KOR could not be detected. However, the indolomorphan 19 and the quinolinomorphan 22 showed nanomolar σ1 receptor affinity (Ki = 58 nM and 20 nM).

以天然产物(R)-香芹酮为原料,分两步制备了对映体纯度极高的 4-羟基吗啡-7-酮。首先,(R)-香芹酮的异丙烯基被转化为环氧化物 7。环氧化物与伯胺发生多米诺反应,然后在 α、β-不饱和酮上与生成的伯胺发生分子内共轭加成反应,从而形成吗喃支架。这种新型吗喃合成方法可以在三个位置上对双环体系进行修饰,从而得到 26 种不同的吗喃。各种伯胺导致了具有不同 N-取代基的吗啡 8-13。酰化或水消除后氢化可得到酯 15 和 16 或不含羟基的吗啡 18。酮 11a 和 12a 与苯甲醛缩合,制备出了亚苄基吗啡 25a 和 26a。最后,利用 11a 和 12a 的 α-亚甲基酮得到了吲哚吗啉、喹啉吗啉、嘧啶吗啉和吡唑吗啉。无法检测到新型吗啡类与阿片受体 MOR、DOR 和 KOR 的亲和力。不过,吲哚吗啡 19 和喹啉吗啡 22 显示出纳摩尔σ1 受体亲和力(Ki = 58 nM 和 20 nM)。
{"title":"Two-step synthesis of enantiomerically pure morphans from (R)-carvone.","authors":"Bernhard Wünsch, Giuliana Costanzo, Giuseppe Cosentino, Lorella Pasquinucci, Emanuele Amata, Dirk Schepmann","doi":"10.1002/cmdc.202400596","DOIUrl":"https://doi.org/10.1002/cmdc.202400596","url":null,"abstract":"<p><p>Enantiomerically pure 4-hydroxymorphan-7-ones were prepared in two steps from the natural product (R)-carvone. At first, the isopropenyl moiety of (R)-carvone was converted into the epoxide 7. A Domino reaction consisting of epoxide opening with primary amines followed by intramolecular conjugate addition of the resulting secondary amines at the α,β-unsaturated ketone established the morphan scaffold. This novel morphan synthesis allowed the modification of the bicyclic system at three positions resulting in 26 diverse morphans. Various primary amines led to morphans 8‒13 with different N-substituents. Acylation or water elimination followed by hydrogenation led to esters 15 and 16 or the morphan 18 without a hydroxy moiety. The benzylidenemorphans 25a and 26a were prepared by condensation of the ketones 11a and 12a with benzaldehyde. Finally, the α-methylene ketone of 11a and 12a was exploited to obtain indolomorphans, quinolinomorphans, pyrimidinomorphans and pyrazolomorphans. Affinity of the novel morphans at opioid receptors MOR, DOR and KOR could not be detected. However, the indolomorphan 19 and the quinolinomorphan 22 showed nanomolar σ1 receptor affinity (Ki = 58 nM and 20 nM).</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leveraging Natural Product-inspired Antifungals to Investigate the Mechanism of Action of Peniciaculin A. 利用天然产品启发的抗真菌药物研究青霉素 A 的作用机制。
IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-09-05 DOI: 10.1002/cmdc.202400500
Ingrid Wilt, Adrian Demeritte, Alexander Kim, Weiwei Wang, William M Wuest

Ubiquinone mimics known as quinone outside inhibitors (QoIs) are one of the most prominent fungicides used to protect crops in the agricultural industry. Due to chemotype similarities with known QoIs, peniciaculin A, a triaryl natural product, was proposed to exhibit similar broad spectrum antifungal activity against phytopathogens. Instability of the tertiary alcohol and phenol motif, however, prompted exploration of the antifungal properties of simplified analogues to probe possible overlap in mechanism of action between the natural product and QoIs. Peniciaculin A inspired analogues mimicking known QoI scaffolds displayed broad spectrum antifungal activity while those containing scaffolds dissimilar to QoIs possessed negligible bioactivity. These activity profiles suggest peniciaculin A is likely acting as a QoI.

被称为醌外抑制剂(QoIs)的泛醌模拟物是农业领域用于保护农作物的最重要的杀真菌剂之一。由于与已知 QoIs 的化学型相似,有人提出三芳基天然产物 peniciaculin A 对植物病原体具有类似的广谱抗真菌活性。然而,叔醇和苯酚基团的不稳定性促使人们探索简化类似物的抗真菌特性,以探究天然产物和 QoIs 之间可能存在的作用机制重叠。模仿已知 QoI 骨架的青霉素 A 灵感类似物显示出广谱抗真菌活性,而那些含有与 QoI 不同骨架的类似物的生物活性则微乎其微。这些活性特征表明,青霉素 A 很可能是一种 QoI。
{"title":"Leveraging Natural Product-inspired Antifungals to Investigate the Mechanism of Action of Peniciaculin A.","authors":"Ingrid Wilt, Adrian Demeritte, Alexander Kim, Weiwei Wang, William M Wuest","doi":"10.1002/cmdc.202400500","DOIUrl":"https://doi.org/10.1002/cmdc.202400500","url":null,"abstract":"<p><p>Ubiquinone mimics known as quinone outside inhibitors (QoIs) are one of the most prominent fungicides used to protect crops in the agricultural industry. Due to chemotype similarities with known QoIs, peniciaculin A, a triaryl natural product, was proposed to exhibit similar broad spectrum antifungal activity against phytopathogens. Instability of the tertiary alcohol and phenol motif, however, prompted exploration of the antifungal properties of simplified analogues to probe possible overlap in mechanism of action between the natural product and QoIs. Peniciaculin A inspired analogues mimicking known QoI scaffolds displayed broad spectrum antifungal activity while those containing scaffolds dissimilar to QoIs possessed negligible bioactivity. These activity profiles suggest peniciaculin A is likely acting as a QoI.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovery of Palindrome Dual PPARγ-GPR40 Agonists for Treating Type 2 Diabetes. 发现用于治疗 2 型糖尿病的 Palindrome 双 PPARγ-GPR40 激动剂。
IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-09-05 DOI: 10.1002/cmdc.202400492
Ana Rodríguez-Luévano, Julio C Almanza-Pérez, Rolffy Ortiz-Andrade, Samuel Lara-González, Rosa Santillán, Gabriel Navarrete-Vázquez, Abraham Giacoman-Martínez, Roberto C Lazzarini-Lechuga, Elihú Bautista, Sergio Hidalgo-Figueroa

This work describes a first attempt of palindromic design for dual compounds that act simultaneously on peroxisome proliferator-activated receptor gamma (PPARg) and G-protein-coupled receptor 40 (GPR40) for the treatment of type 2 diabetes. The compounds were synthesized by multi-step chemical reactions and the relative mRNA expression levels of PPARg, GPR40, and GLUT-4 were measured in cultured C2C12 muscle cells and RIN-m5f b-pancreatic cells. In addition, insulin secretion and GLUT-4 translocation were measured. Compound 2 displayed a moderate increase in the mRNA expression of PPARg and GPR40. However, the translocation of the GLUT-4 transporter was 400% with a similar effect to pioglitazone. The in vivo effect of compound 2 was determined at 25 mg/kg single dose using a normoglycemic and non-insulin dependent diabetes mellitus (NIDDM) rat models. Compound 2 showed basal plasma glucose in diabetic rats with feed intake, which is associated with the moderate release of insulin measured in cells. Surprisingly, the glucose does not decrease in normoglycemic rats. Compound 2 maintained significant interactions with the GPR40 and PPARg receptors during molecular dynamics. Altogether, the results demonstrate that compound 2, with a palindromic design, simultaneously activates PPARg and GPR40 receptors without inducing hypoglycemia.

这项研究首次尝试了同时作用于过氧化物酶体增殖激活受体γ(PPARg)和G蛋白偶联受体40(GPR40)的双化合物的回文设计,用于治疗2型糖尿病。这些化合物是通过多步化学反应合成的,并在培养的 C2C12 肌肉细胞和 RIN-m5f b 型胰腺细胞中测定了 PPARg、GPR40 和 GLUT-4 的相对 mRNA 表达水平。此外,还测定了胰岛素分泌和 GLUT-4 转位。化合物 2 可适度增加 PPARg 和 GPR40 的 mRNA 表达。然而,GLUT-4 转运体的转位增加了 400%,效果与吡格列酮相似。使用正常血糖大鼠和非胰岛素依赖型糖尿病(NIDDM)大鼠模型测定了化合物 2 的体内效应,单剂量为 25 毫克/千克。化合物 2 显示,糖尿病大鼠的基础血浆葡萄糖与饲料摄入量有关,这与细胞中测得的胰岛素适度释放有关。令人惊讶的是,血糖正常大鼠的血糖并没有降低。化合物 2 在分子动力学过程中与 GPR40 和 PPARg 受体保持着明显的相互作用。总之,研究结果表明,采用回文设计的化合物 2 可同时激活 PPARg 和 GPR40 受体,而不会诱发低血糖症。
{"title":"Discovery of Palindrome Dual PPARγ-GPR40 Agonists for Treating Type 2 Diabetes.","authors":"Ana Rodríguez-Luévano, Julio C Almanza-Pérez, Rolffy Ortiz-Andrade, Samuel Lara-González, Rosa Santillán, Gabriel Navarrete-Vázquez, Abraham Giacoman-Martínez, Roberto C Lazzarini-Lechuga, Elihú Bautista, Sergio Hidalgo-Figueroa","doi":"10.1002/cmdc.202400492","DOIUrl":"https://doi.org/10.1002/cmdc.202400492","url":null,"abstract":"<p><p>This work describes a first attempt of palindromic design for dual compounds that act simultaneously on peroxisome proliferator-activated receptor gamma (PPARg) and G-protein-coupled receptor 40 (GPR40) for the treatment of type 2 diabetes. The compounds were synthesized by multi-step chemical reactions and the relative mRNA expression levels of PPARg, GPR40, and GLUT-4 were measured in cultured C2C12 muscle cells and RIN-m5f b-pancreatic cells. In addition, insulin secretion and GLUT-4 translocation were measured. Compound 2 displayed a moderate increase in the mRNA expression of PPARg and GPR40. However, the translocation of the GLUT-4 transporter was 400% with a similar effect to pioglitazone. The in vivo effect of compound 2 was determined at 25 mg/kg single dose using a normoglycemic and non-insulin dependent diabetes mellitus (NIDDM) rat models. Compound 2 showed basal plasma glucose in diabetic rats with feed intake, which is associated with the moderate release of insulin measured in cells. Surprisingly, the glucose does not decrease in normoglycemic rats. Compound 2 maintained significant interactions with the GPR40 and PPARg receptors during molecular dynamics. Altogether, the results demonstrate that compound 2, with a palindromic design, simultaneously activates PPARg and GPR40 receptors without inducing hypoglycemia.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor-Associated Carbohydrate Antigen 19-9 (CA 19-9), a Promising Target for Antibody-Based Detection, Diagnosis, and Immunotherapy of Cancer. 肿瘤相关碳水化合物抗原 19-9 (CA19-9)--基于抗体的癌症检测、诊断和免疫疗法的有望靶点。
IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-09-04 DOI: 10.1002/cmdc.202400491
Athar Nakisa, Lorenzo F Sempere, Xi Chen, Linda T Qu, Daniel Woldring, Howard C Crawford, Xuefei Huang

Carbohydrate antigen 19-9 (CA 19-9) also known as sialyl Lewis A is a tetrasaccharide overexpressed on a wide range of cancerous cells, which has been detected at elevated levels in sera of patients with various types of malignancies, most prominently pancreatic ductal adenocarcinoma. After its identification in 1979, multiple studies have highlighted the significant roles of CA 19-9 in cancer progression, including facilitating extravasation and eventually metastases, proliferation of cancer cells, and suppression of the immune system. Therefore, CA 19-9 has been considered an attractive target for cancer diagnosis, prognosis, and therapy. This review discusses the synthesis of CA 19-9 antigen, elicitation of antibodies through vaccination, development of anti-CA 19-9 monoclonal antibodies, and their applications as imaging tracers and therapeutics for a variety of CA 19-9-positive cancer.

碳水化合物抗原 19-9(CA 19-9)又称 sialyl Lewis A,是一种在多种癌细胞上过度表达的四糖,在各类恶性肿瘤(最常见的是胰腺导管腺癌)患者的血清中检测到其含量升高。自 1979 年发现 CA 19-9 后,多项研究都强调了它在癌症进展过程中的重要作用,包括促进癌细胞外渗并最终转移、癌细胞增殖以及抑制免疫系统。因此,CA 19-9 被认为是癌症诊断、预后和治疗的一个有吸引力的靶点。本综述将讨论 CA 19-9 抗原的合成、通过疫苗接种激发抗体、抗 CA 19-9 单克隆抗体的开发,以及它们作为成像示踪剂和治疗各种 CA 19-9 阳性癌症的应用。
{"title":"Tumor-Associated Carbohydrate Antigen 19-9 (CA 19-9), a Promising Target for Antibody-Based Detection, Diagnosis, and Immunotherapy of Cancer.","authors":"Athar Nakisa, Lorenzo F Sempere, Xi Chen, Linda T Qu, Daniel Woldring, Howard C Crawford, Xuefei Huang","doi":"10.1002/cmdc.202400491","DOIUrl":"https://doi.org/10.1002/cmdc.202400491","url":null,"abstract":"<p><p>Carbohydrate antigen 19-9 (CA 19-9) also known as sialyl Lewis A is a tetrasaccharide overexpressed on a wide range of cancerous cells, which has been detected at elevated levels in sera of patients with various types of malignancies, most prominently pancreatic ductal adenocarcinoma. After its identification in 1979, multiple studies have highlighted the significant roles of CA 19-9 in cancer progression, including facilitating extravasation and eventually metastases, proliferation of cancer cells, and suppression of the immune system. Therefore, CA 19-9 has been considered an attractive target for cancer diagnosis, prognosis, and therapy. This review discusses the synthesis of CA 19-9 antigen, elicitation of antibodies through vaccination, development of anti-CA 19-9 monoclonal antibodies, and their applications as imaging tracers and therapeutics for a variety of CA 19-9-positive cancer.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142131375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zn(II)-curcumin complexes-based anticancer agents. 基于 Zn(II)-curcumin 复合物的抗癌剂。
IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-09-03 DOI: 10.1002/cmdc.202400558
Sankarasekaran Shanmugaraju, Rajdeep Mondal, Muthukumar Keerthana, Nanjan Pandurangan

There is a great deal of research interest in the design of alternative metallodrugs to Pt(II)-derivatives for cancer treatment. The low solubility of such drugs in biological mediums leading to poor bioavailability is the major hurdle of several metal-based anticancer agents. These issues have recently been addressed by designing bio-active ligands based on metal-containing anticancer agents. Conjugating with bioactive ligands has significantly improved the bioavailability of the metallodrugs and their cancer cell targeting ability. One such naturally available bioactive ligand is curcumin. Until recently, several curcumin-based anticancer metallodrugs have been developed and successfully demonstrated for their anticancer studies. In this article, we aim to highlight, the synthesis, structure, and anticancer properties of various Zn(II)-curcumin-based coordination complexes. The effect of introducing different functional groups, targeting ligands, and photo-active ligands on the anticancer potential of such complexes has been mentioned in detail. The current status and future perspective on curcumin-based metallodrugs for cancer treatment have also been stated.

人们对设计用于治疗癌症的铂(II)衍生物的替代金属药物有着浓厚的研究兴趣。这类药物在生物介质中的溶解度低,导致生物利用率低,是几种金属抗癌剂的主要障碍。最近,人们通过设计基于含金属抗癌剂的生物活性配体来解决这些问题。与生物活性配体共轭可显著提高金属药物的生物利用度及其癌细胞靶向能力。姜黄素就是这样一种天然生物活性配体。直到最近,一些基于姜黄素的抗癌金属药物已经被开发出来,并成功地进行了抗癌研究。在本文中,我们将重点介绍各种基于姜黄素的锌(II)配位复合物的合成、结构和抗癌特性。文章还详细介绍了引入不同官能团、靶向配体和光活性配体对此类配合物抗癌潜力的影响。此外,还阐述了姜黄素类金属药物治疗癌症的现状和未来前景。
{"title":"Zn(II)-curcumin complexes-based anticancer agents.","authors":"Sankarasekaran Shanmugaraju, Rajdeep Mondal, Muthukumar Keerthana, Nanjan Pandurangan","doi":"10.1002/cmdc.202400558","DOIUrl":"https://doi.org/10.1002/cmdc.202400558","url":null,"abstract":"<p><p>There is a great deal of research interest in the design of alternative metallodrugs to Pt(II)-derivatives for cancer treatment. The low solubility of such drugs in biological mediums leading to poor bioavailability is the major hurdle of several metal-based anticancer agents. These issues have recently been addressed by designing bio-active ligands based on metal-containing anticancer agents. Conjugating with bioactive ligands has significantly improved the bioavailability of the metallodrugs and their cancer cell targeting ability. One such naturally available bioactive ligand is curcumin. Until recently, several curcumin-based anticancer metallodrugs have been developed and successfully demonstrated for their anticancer studies. In this article, we aim to highlight, the synthesis, structure, and anticancer properties of various Zn(II)-curcumin-based coordination complexes. The effect of introducing different functional groups, targeting ligands, and photo-active ligands on the anticancer potential of such complexes has been mentioned in detail. The current status and future perspective on curcumin-based metallodrugs for cancer treatment have also been stated.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142118540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fluorescence-Based HTS Assays for Ion Channel Modulation in Drug Discovery Pipelines. 基于荧光的 HTS 检测法,用于药物研发流程中的离子通道调节。
IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-09-02 DOI: 10.1002/cmdc.202400383
Jan Voldřich, Marika Matoušová, Markéta Šmídková, Helena Mertlikova-Kaiserova

Ion channels represent a druggable family of transmembrane pore-forming proteins with important (patho)physiological functions. While electrophysiological measurement (manual patch clamp) remains the only direct method for detection of ion currents, it is a labor-intensive technique. Although automated patch clamp instruments have become available to date, their high costs limit their use to large pharma companies or commercial screening facilities. Therefore, fluorescence-based assays are particularly important for initial screening of compound libraries. Despite their numerous disadvantages, they are highly amenable to high-throughput screening and in many cases, no sophisticated instrumentation or materials are required. These features predispose them for implementation in early phases of drug discovery pipelines (hit identification), even in an academic environment. This review summarizes the advantages and pitfalls of individual methodological approaches for identification of ion channel modulators employing fluorescent probes (i.e., membrane potential and ion flux assays) with emphasis on practical aspects of their adaptation to high-throughput format.

离子通道是一个可药物治疗的跨膜孔形成蛋白家族,具有重要的(病理)生理功能。尽管电生理测量(手动膜片钳)仍是检测离子电流的唯一直接方法,但这是一项劳动密集型技术。虽然目前已有自动膜片钳仪器,但其高昂的成本限制了大型制药公司或商业筛选机构的使用。因此,基于荧光的检测方法对于化合物库的初步筛选尤为重要。尽管荧光检测法有许多缺点,但它们非常适合高通量筛选,而且在许多情况下不需要复杂的仪器或材料。这些特点使它们能够在药物发现流水线的早期阶段(新药鉴定)使用,即使在学术环境中也是如此。本综述总结了利用荧光探针(即膜电位和离子通量测定法)鉴定离子通道调节剂的各种方法的优势和缺陷,重点介绍了这些方法适应高通量格式的实用性方面。
{"title":"Fluorescence-Based HTS Assays for Ion Channel Modulation in Drug Discovery Pipelines.","authors":"Jan Voldřich, Marika Matoušová, Markéta Šmídková, Helena Mertlikova-Kaiserova","doi":"10.1002/cmdc.202400383","DOIUrl":"https://doi.org/10.1002/cmdc.202400383","url":null,"abstract":"<p><p>Ion channels represent a druggable family of transmembrane pore-forming proteins with important (patho)physiological functions. While electrophysiological measurement (manual patch clamp) remains the only direct method for detection of ion currents, it is a labor-intensive technique. Although automated patch clamp instruments have become available to date, their high costs limit their use to large pharma companies or commercial screening facilities. Therefore, fluorescence-based assays are particularly important for initial screening of compound libraries. Despite their numerous disadvantages, they are highly amenable to high-throughput screening and in many cases, no sophisticated instrumentation or materials are required. These features predispose them for implementation in early phases of drug discovery pipelines (hit identification), even in an academic environment. This review summarizes the advantages and pitfalls of individual methodological approaches for identification of ion channel modulators employing fluorescent probes (i.e., membrane potential and ion flux assays) with emphasis on practical aspects of their adaptation to high-throughput format.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142102575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Front Cover: Prodrug Approach to Exploit (S)-Alanine Amide as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors (ChemMedChem 17/2024) 封面:利用(S)-丙氨酸酰胺作为精氨酸模拟分子开发蛋白精氨酸甲基转移酶 4 抑制剂的原药方法(ChemMedChem 17/2024)
IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-09-02 DOI: 10.1002/cmdc.202481701
Prof. Dr. Ciro Milite, Giuliana Sarno, Ida Pacilio, Dr. Agostino Cianciulli, Dr. Monica Viviano, Dr. Giulia Iannelli, Erica Gazzillo, Dr. Alessandra Feoli, Dr. Alessandra Cipriano, Prof. Dr. Maria Giovanna Chini, Prof. Dr. Sabrina Castellano, Prof. Dr. Giuseppe Bifulco, Prof. Dr. Gianluca Sbardella

The front cover picture shows that the introduction of a NAD(P)H:quinone oxidoreductase 1 (NQO1)-responsive trigger group (in cyan sticks) to mask the S-alanine amido group turns PRMT4 inhibitors (in orange sticks) into cell-permeable prodrugs, that after in cell activation (magenta) are able to inhibit PRMT4 (yellow green) and reduce arginine dimethylation of the PRMT4 substrates BRG1-associated factor 155 (BAF155). More details can be found in the Research Article by Maria Giovanna Chini, Sabrina Castellano, and co-workers. Cover design by Gianluca Sbardella.

封面图片显示,引入一个 NAD(P)H:醌氧化还原酶 1 (NQO1) 响应触发基团(青色条纹)掩盖了 S-丙氨酸氨基基团,使 PRMT4 抑制剂(橙色条纹)变成了细胞渗透性原药,在细胞内活化(品红色)后能够抑制 PRMT4(黄绿色)并减少 PRMT4 底物 BRG1 相关因子 155(BAF155)的精氨酸二甲基化。更多详情,请参阅 Maria Giovanna Chini、Sabrina Castellano 及其合作者的研究文章。封面设计:Gianluca Sbardella。
{"title":"Front Cover: Prodrug Approach to Exploit (S)-Alanine Amide as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors (ChemMedChem 17/2024)","authors":"Prof. Dr. Ciro Milite,&nbsp;Giuliana Sarno,&nbsp;Ida Pacilio,&nbsp;Dr. Agostino Cianciulli,&nbsp;Dr. Monica Viviano,&nbsp;Dr. Giulia Iannelli,&nbsp;Erica Gazzillo,&nbsp;Dr. Alessandra Feoli,&nbsp;Dr. Alessandra Cipriano,&nbsp;Prof. Dr. Maria Giovanna Chini,&nbsp;Prof. Dr. Sabrina Castellano,&nbsp;Prof. Dr. Giuseppe Bifulco,&nbsp;Prof. Dr. Gianluca Sbardella","doi":"10.1002/cmdc.202481701","DOIUrl":"https://doi.org/10.1002/cmdc.202481701","url":null,"abstract":"<p>The front cover picture shows that the introduction of a NAD(P)H:quinone oxidoreductase 1 (NQO1)-responsive trigger group (in cyan sticks) to mask the S-alanine amido group turns PRMT4 inhibitors (in orange sticks) into cell-permeable prodrugs, that after in cell activation (magenta) are able to inhibit PRMT4 (yellow green) and reduce arginine dimethylation of the PRMT4 substrates BRG1-associated factor 155 (BAF155). More details can be found in the Research Article by Maria Giovanna Chini, Sabrina Castellano, and co-workers. Cover design by Gianluca Sbardella.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202481701","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142123174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lactam Truncation Yields a Dihydroquinazolinone Scaffold with Potent Antimalarial Activity that Targets PfATP4. 内酰胺截短产生的二氢喹唑啉酮支架具有针对 PfATP4 的强效抗疟活性。
IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-08-30 DOI: 10.1002/cmdc.202400549
Trent D Ashton, Petar P S Calic, Madeline G Dans, Zi Kang Ooi, Qingmiao Zhou, Katie Loi, Kate E Jarman, Josephine Palandri, Deyun Qiu, Adele M Lehane, Bikash Maity, Nirupam De, Mufuliat T Famodimu, Michael J Delves, Emma Y Mao, Maria R Gancheva, Danny W Wilson, Mrittika Chowdury, Tania F de Koning-Ward, Delphine Baud, Stephen Brand, Paul F Jackson, Alan F Cowman, Brad E Sleebs

The emergence of resistance against current antimalarial treatments has necessitated the need for the development of novel antimalarial chemotypes. Toward this goal, we recently optimised the antimalarial activity of the dihydroquinazolinone scaffold and showed it targeted PfATP4. Here, we deconstruct the lactam moiety of the tricyclic dihydroquinazolinone scaffold and investigate the structure-activity relationship of the truncated scaffold. It was shown that SAR between scaffolds was largely transferrable and generated analogues with potent asexual stage activity. Evaluation of the truncated analogues against PfATP4 mutant drug resistant parasite strains and in assays measuring PfATP4-associated ATPase activity demonstrated retention of PfATP4 as the molecular target. Analogues exhibited activity against both male and female gametes and multidrug resistant parasites. Limited efficacy of analogues in a P. berghei asexual stage mouse model was attributed to their moderate metabolic stability and low aqueous stability. Further development is required to address these attributes toward the potential use of the dihydroquinazolinone class in a curative and transmission blocking combination antimalarial therapy.

由于目前的抗疟药物出现了抗药性,因此有必要开发新型抗疟药物。为了实现这一目标,我们最近优化了二氢喹唑啉酮支架的抗疟活性,并证明它能靶向 PfATP4。在这里,我们解构了三环二氢喹唑啉酮支架的内酰胺分子,并研究了截短支架的结构-活性关系。结果表明,支架之间的 SAR 在很大程度上是可以转移的,并产生了具有强效无性阶段活性的类似物。针对 PfATP4 突变抗药性寄生虫菌株以及在测量 PfATP4 相关 ATPase 活性的试验中对截短类似物进行的评估表明,PfATP4 仍是分子靶标。类似物对雌雄配子和耐多药寄生虫都具有活性。类似物在小鼠无性阶段伯格希氏疟原虫模型中的疗效有限,原因是它们的代谢稳定性一般,水稳定性较低。要解决这些问题,还需要进一步开发二氢喹唑啉酮类药物,以便将其用于治疗和阻断传播的联合抗疟疗法。
{"title":"Lactam Truncation Yields a Dihydroquinazolinone Scaffold with Potent Antimalarial Activity that Targets PfATP4.","authors":"Trent D Ashton, Petar P S Calic, Madeline G Dans, Zi Kang Ooi, Qingmiao Zhou, Katie Loi, Kate E Jarman, Josephine Palandri, Deyun Qiu, Adele M Lehane, Bikash Maity, Nirupam De, Mufuliat T Famodimu, Michael J Delves, Emma Y Mao, Maria R Gancheva, Danny W Wilson, Mrittika Chowdury, Tania F de Koning-Ward, Delphine Baud, Stephen Brand, Paul F Jackson, Alan F Cowman, Brad E Sleebs","doi":"10.1002/cmdc.202400549","DOIUrl":"https://doi.org/10.1002/cmdc.202400549","url":null,"abstract":"<p><p>The emergence of resistance against current antimalarial treatments has necessitated the need for the development of novel antimalarial chemotypes. Toward this goal, we recently optimised the antimalarial activity of the dihydroquinazolinone scaffold and showed it targeted PfATP4. Here, we deconstruct the lactam moiety of the tricyclic dihydroquinazolinone scaffold and investigate the structure-activity relationship of the truncated scaffold. It was shown that SAR between scaffolds was largely transferrable and generated analogues with potent asexual stage activity. Evaluation of the truncated analogues against PfATP4 mutant drug resistant parasite strains and in assays measuring PfATP4-associated ATPase activity demonstrated retention of PfATP4 as the molecular target. Analogues exhibited activity against both male and female gametes and multidrug resistant parasites. Limited efficacy of analogues in a P. berghei asexual stage mouse model was attributed to their moderate metabolic stability and low aqueous stability. Further development is required to address these attributes toward the potential use of the dihydroquinazolinone class in a curative and transmission blocking combination antimalarial therapy.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142102576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How to Find a Fragment: Methods for Screening and Validation in Fragment-Based Drug Dscovery. 如何寻找片段:基于片段的药物研发中的筛选和验证方法》(How Find the Fragment: Methods for Screening and Validation in Fragment-Based Drug Dscovery)。
IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-08-28 DOI: 10.1002/cmdc.202400342
Tim Kirkman, Catharina Dos Santos Silva, Manuela Tosin, Marcio Vinicius Bertacine Dias

Fragment-based drug discovery (FBDD) is a crucial strategy for developing new drugs that have been applied to diverse targets, from neglected infectious diseases to cancer. With at least seven drugs already launched to the market, this approach has gained interest in both academics and industry in the last 20 years. FBDD relies on screening small libraries with about 1000-2000 compounds of low molecular weight (about 300 Da) using several biophysical methods. Because of the reduced size of the compounds, the chemical space and diversity can be better explored than large libraries used in high throughput screenings. This review summarises the most common biophysical techniques used in fragment screening and orthogonal validation. We also explore the advantages and drawbacks of the different biophysical techniques and examples of applications and strategies.

片段药物发现(FBDD)是开发新药的重要策略,已被应用于从被忽视的传染病到癌症等不同靶点。在过去的 20 年中,至少有 7 种药物已经投放市场,因此这种方法在学术界和工业界都引起了极大的兴趣。FBDD 依赖于使用多种生物物理方法筛选约 1000-2000 个低分子量(约 300 Da)化合物的小型文库。与高通量筛选中使用的大型化合物库相比,由于化合物的体积缩小,可以更好地探索化学空间和多样性。本综述总结了片段筛选和正交验证中最常用的生物物理技术。我们还探讨了不同生物物理技术的优缺点以及应用实例和策略。
{"title":"How to Find a Fragment: Methods for Screening and Validation in Fragment-Based Drug Dscovery.","authors":"Tim Kirkman, Catharina Dos Santos Silva, Manuela Tosin, Marcio Vinicius Bertacine Dias","doi":"10.1002/cmdc.202400342","DOIUrl":"https://doi.org/10.1002/cmdc.202400342","url":null,"abstract":"<p><p>Fragment-based drug discovery (FBDD) is a crucial strategy for developing new drugs that have been applied to diverse targets, from neglected infectious diseases to cancer. With at least seven drugs already launched to the market, this approach has gained interest in both academics and industry in the last 20 years. FBDD relies on screening small libraries with about 1000-2000 compounds of low molecular weight (about 300 Da) using several biophysical methods. Because of the reduced size of the compounds, the chemical space and diversity can be better explored than large libraries used in high throughput screenings. This review summarises the most common biophysical techniques used in fragment screening and orthogonal validation. We also explore the advantages and drawbacks of the different biophysical techniques and examples of applications and strategies.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142091249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
ChemMedChem
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1